doi: 10.3389/fimmu.2025.1709561 Received 20 September 2025 Revised 16 October 2025 Accepted 11 November 2025 Published 26 November 2025 Volume 16 - 2025 Edited by Juan Pablo de Rivero Vaccari, University of Miami, United States Reviewed by Emir Malovic, University of Illinois Chicago, United States Anna Maria Sardanelli, University of Bari Aldo Moro, Italy Updates Copyright 2025 Tu, Han, Zhang, Jia, Sun, Liu, Li, Tang and Wang
Conclusions GLP-1RAs are effective at improving glycaemic control and, by virtue of their mechanism of action, have a low risk of hypoglycaemia combined with the potential for weight loss
[9] The GLP-1 Mechanism, Organ by Organ The body naturally produces GLP-1 in the L-cells of the small intestine when food is eaten
This report provides an in-depth examination of how the electronic prior authorization process works for GLP-1 drugs
Look for extracts standardized to withanolides (typically 2.5-5%), with common dosages ranging from 300-600mg daily